Clinical and laboratory outcomes of the solid cancer patients reinfected with SARS-CoV-2.

Ünsal O., Yazıcı O., Özdemir N., Çubukçu E., Ocak B., Üner A., ...Daha Fazla

Future oncology (London, England), cilt.18, ss.533-541, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2021-0621
  • Dergi Adı: Future oncology (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.533-541
  • Anahtar Kelimeler: COVID-19, reinfection, SARS-CoV-2, solid cancer, RISK-FACTORS, COVID-19, MULTICENTER, MORTALITY, CHINA
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Lay abstract Solid cancer patients are at a higher risk than general population in terms of Coronavirus disease 2019 (COVID-19) infectivity and COVID-19-associated death and disease. It is also known that COVID-19 infection has a more severe course in immunocompromised patients. Solid cancer patients may be a vulnerable subgroup of patients to reinfection with COVID-19. The rate of reinfection was 3.1% (n = 32) in our study population of 1024 solid cancer patients who were tested positive on a COVID-19 PCR test. The death rate of the patients with solid cancer was 34.3% (n = 11). In addition, we demonstrated that intensive care follow-up is significantly longer during the reinfection period. It was demonstrated that the time between the last dose of chemotherapy for the patients and the reinfection COVID PCR positivity did not affect the death rate. The COVID-19 pandemic has affected people's daily lives and treatments in many aspects. Owing to the high death rate of reinfection, even if cancer patients have reinfection, our approach is to continue cancer treatment as soon as the patient is cured. Finally, we support the priority vaccination of cancer patients.